In previously untreated “double-expresser” patients, combining tucidinostat with standard R-CHOP chemotherapy resulted in better complete response and event-free survival rates than R-CHOP alone.
MDedge News
Source link : https://www.medscape.com/s/viewarticle/double-expresser-dlbcl-tucidinostat-improved-r-chop-outcomes-2024a1000d7b?src=rss
Author :
Publish date : 2024-07-18 10:33:31
Copyright for syndicated content belongs to the linked Source.
